



**Decision: PMPRB-12-D1-TACTUO
- Board Order**

**IN THE MATTER OF the *Patent Act* R.S.C. 1985, c. P-4,
as amended**

**AND IN THE MATTER OF Galderma Canada Inc.
(the "Respondent") and the medicine "Tactuo"**

ORDER

Pursuant to section 83 of the *Patent Act*, the Patented Medicine Prices Review Board (the "Board") issued a Notice of Hearing on September 26, 2012, pertaining to allegations of Board Staff that the medicine Tactuo had been, and was being, sold by Galderma Canada Inc. ("Galderma") in Canada at prices greater than the prices calculated in accordance with the Board's Guidelines.

On December 13, 2012, Galderma and Board Staff filed a Joint Submission providing a draft Voluntary Compliance Undertaking ("VCU") by which it proposed to resolve all issues raised in these proceedings.

The Board has decided to accept Galderma's VCU, effective as of the date of this Order.

The Board Members underscore that the acceptance of the attached VCU is premised on the specific facts presented in this case and is not to be interpreted as recognition of any policy change in how the Board's Guidelines are interpreted.

Accordingly, by Order of this Board the proceeding that was commenced by the issuance of the Notice of Hearing is hereby concluded.

Board Members: Thomas (Tim) Armstrong
Normand Tremblay

Board Counsel: Anil K. Kapoor

Original signed by
Sylvie Dupont
Secretary of the Board

April 24, 2013

